Metrological approaches to drug development. Fast screening using universal biosensors at the stage of drug development
作者： S. E. Kondakov , M. Ya. Mel’nikov , K. G. Fedorenko , O. S. Prokoptseva
DOI: 10.1134/S1070363212030322
关键词:
摘要: We expect that in the near future drug development will become most interesting and demanded application of suggested approach. Taking a known as reference point performing its chemical modification, one can sharply reduce time financial expenses for bioactivity testing new substances experimentally predict general toxicity on biological model adequate to human body.
springer.com
sci-hub.se 参考文章(33)
Gerald M. Higa, Miklos L. Auber, Nabiel AlKhouri, Elevation of the Erythrocyte Sedimentation Rate Precedes Exacerbation of Bleomycin‐Induced Pulmonary Toxicity: Report of Two Cases and Review of Literature Pharmacotherapy. ,vol. 17, pp. 1315- 1321 ,(1997) , 10.1002/J.1875-9114.1997.TB03099.X
Pratik Banerjee, Dominik Lenz, Joseph Paul Robinson, Jenna L Rickus, Arun K Bhunia, A novel and simple cell-based detection system with a collagen-encapsulated B-lymphocyte cell line as a biosensor for rapid detection of pathogens and toxins. Laboratory Investigation. ,vol. 88, pp. 196- 206 ,(2008) , 10.1038/LABINVEST.3700703
Mohamed Diwan M. AbdulHameed, Adel Hamza, Junjun Liu, Chang-Guo Zhan, Combined 3D-QSAR Modeling and Molecular Docking Study on Indolinone Derivatives as Inhibitors of 3-Phosphoinositide-Dependent Protein Kinase-1 Journal of Chemical Information and Modeling. ,vol. 48, pp. 1760- 1772 ,(2008) , 10.1021/CI800147V
T Lynn Riggs, Research and development costs for drugs. The Lancet. ,vol. 363, pp. 184- 184 ,(2004) , 10.1016/S0140-6736(03)15370-6
Jocelyn H Ng, Leodevico L Ilag, Streamlining drug discovery: finding the right drug against the right target to treat the right disease Drug Discovery Today. ,vol. 9, pp. 59- 60 ,(2004) , 10.1016/S1359-6446(03)02935-0
S. FU, J.J. KAVANAGH, W. HU, R.C. BAST, Clinical application of oxaliplatin in epithelial ovarian cancer. International Journal of Gynecological Cancer. ,vol. 16, pp. 1717- 1732 ,(2006) , 10.1111/J.1525-1438.2006.00654.X
C Lowe, An introduction to the concepts and technology of biosensors Biosensors. ,vol. 1, pp. 3- 16 ,(1985) , 10.1016/0265-928X(85)85004-5
Richard G Frank, New estimates of drug development costs. Journal of Health Economics. ,vol. 22, pp. 325- 330 ,(2003) , 10.1016/S0167-6296(03)00002-X
Patricia Connolly, Clinical diagnostics opportunities for biosensors and bioelectronics Biosensors and Bioelectronics. ,vol. 10, pp. 1- 6 ,(1995) , 10.1016/0956-5663(95)96789-2
Joseph A. DiMasi, Henry G. Grabowski, The cost of biopharmaceutical R&D: is biotech different? Managerial and Decision Economics. ,vol. 28, pp. 469- 479 ,(2007) , 10.1002/MDE.1360